Abstract:SESSION TITLE: Mechanisms of Lung Cancer SESSION TYPE: Original Investigation Slide PRESENTED ON: Saturday, April 16, 2016 at 02:15 PM - 03:45 PM PURPOSE: To describe the importance of using EGFR mutation detection to guide the treatment of patients with NSCLC. METHODS: 3132 (1301 patients had EGFR mutation detections; 1831 patients did not) stage IV NSCLC patients identified through the Shanghai Chest Hospital databases from January 2000 to December 2013. were studied in this retrospective analysis. RESULTS: EGFR tyrosine kinase inhibitor (TKI) therapy was associated with improved OS in common EGFR mutant patients (adjusted HR, 0.25, 95% CI, 0.18-0.35; P < 0.001), uncommon EGFR mutant patients (aHR, 0.44, 95% CI, 0.20-0.99; P = 0.048) and patients of unknown EGFR mutation status (aHR, 0.73, 95% CI, 0.61-0.88; P = 0.001). For EGFR wild-type patients, TKIs failed to improved OS (aHR, 0.97, 95% CI, 0.75-1.26; P = 0.837). For 575 common EGFR mutant patients, TKIs plus 2+ line chemotherapy was associated with improved OS, compared with TKIs alone (aHR, 0.50, 95% CI, 0.37-0.69; P < 0.001) or TKIs plus 1 line chemotherapy (aHR, 0.73, 95% CI, 0.54-0.98; P = 0.037). Among 200 EGFR mutant patients receiving TKIs plus 2+ line chemotherapy, first line TKIs provided improved OS, compared with third+ line TKI therapy (aHR, 0.59, 95% CI, 0.35-0.98; P = 0.043). Compared with second line TKI therapy, first line did not show a significantly improved OS (aHR, 0.98, 95% CI, 0.61-1.58; P = 0.93). CONCLUSIONS: EGFR mutation detection helped to select a subgroup of patients with common EGFR mutations who exhibited the best response to TKIs. First line TKIs treatment provided the best survival for common EGFR mutant patients. Chemotherapy was also a non-negligible aspect of NSCLC treatment. CLINICAL IMPLICATIONS: EGFR gene detection helped to subclassify patients with NSCLC and to select EGFR TKI therapy for patients with common EGFR mutations to achieve the greatest likelihood of long-term survival. Patients who are positive for common EGFR mutations should be treated with EGFR TKIs as first line therapy. Chemotherapy still plays an important role in the treatment of patients harboring EGFR mutations. DISCLOSURE: The following authors have nothing to disclose: Baohui Han, Jianlin Xu, Bo Jin, Tianqing Chu, Yuqing Lou, Xue Dong, Xueyan Zhang, Huiming Wang, Hua Zhong, Chunlei Shi, Aiqing Gu, Liwen Xiong, Yizhuo Zhao, Liyan Jiang, Jie Zhang No Product/Research Disclosure Information

Genomic characterization of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-TKIs for EGFR mutated non-small cell lung cancer

Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment

Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

The Impact of Precision EGFR Mutation Detection on the Treatment Patterns and Outcomes of Patients with Non-small Cell Lung Cancer (NSCLC): A Real-World Study in China

Effect of EGFR amplification on survival of patients with EGFR mutation-positive non-small cell lung cancer.

Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer

Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients

Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer

Ctdna Assessment of EGFR Mutation Status in Chinese Patients with Advanced Non-Small Cell Lung Cancer in Real-World Setting

Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing

Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

Different First Line EGFR-TKI Regimen and the Clearance of EGFR Sensitive Mutation in Acquired EGFR-TKI Resistant Lung Adenocarcinoma Patients

Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing